Bio-Rad研討會：研究人員使用 ProteOn? XPR36 系統研究癌癥、阿爾茨海默病和其他疾病的潛在機制

發布時間： 2012年9月25日

加利福尼亞州赫拉克勒斯 — 2012 年 9 月 25 日 — Bio-Rad 實驗室公司宣布擴展蛋白質功能部門正在進行的 ProteOn 網絡研討會系列，該系列展示了利用 ProteOn XPR36 蛋白質相互作用陣列系統的最新癌癥和疾病研究，該系統是一種使用表面等離子體共振 （SPR） 生成豐富、無標記動力學結合數據的儀器。先前提出的主題包括使用SPR鑒定和表征與癌癥相關的磷酸肌醇信號脂質，以及旨在了解與阿爾茨海默病等神經退行性疾病相關的蛋白質錯誤折疊，聚集和組織沉積的研究。

“網絡研討會介紹了SPR技術在藥物發現工作流程中的最新應用，并為儀器的軟件和硬件提供了有價值的更新，”瑞士羅氏Glycart抗體工程組負責人Ralf J. Hosse博士說。

癌癥和阿爾茨海默病應用

在 2012 年 7 月的網絡研討會上，英國曼徹斯特帕特森癌癥研究所的 Lily Sommer 博士描述了使用 ProteOn XPR36 系統鑒定和表征新型磷酸肌醇結合蛋白的方法。磷酸肌醇是信號脂質，其失調與癌癥有關。這些研究是使用 Bio-Rad 的 ProteOn 脂質體捕獲試劑盒進行的，該試劑盒使用 DNA 雜交選擇性捕獲脂質體以檢測磷酸肌醇-蛋白質相互作用。

意大利米蘭馬里奧·內格里研究所的Marco Gobbi主持了一場題為“SPR在研究淀粉樣蛋白肽和蛋白質中的新應用”的網絡研討會。他討論了用于突變分析和研究抗淀粉樣蛋白候選藥物效果的新型SPR篩選應用。這項工作的結果于2012年6月發表在《生物化學雜志》上。

越來越多的疾病現在與特定蛋白質的錯誤折疊、聚集和組織沉積有關，例如阿爾茨海默病。淀粉樣蛋白-β （A?） 肽的可溶性低聚物在阿爾茨海默病的發病機制中起關鍵作用，但其難以捉摸的性質使檢測具有挑戰性。Gobbi和他的團隊證明，SPR測量對于淀粉樣纖維伸長的動力學分析和可溶性低聚物質的檢測特別有用，這是其他技術無法實現的。

SPR上的最好實踐

網絡研討會系列以會議拉開序幕，該會議側重于以色列魏茨曼科學研究所的Gideon Schreiber教授制定的指南，為研究人員提供如何最好地執行無標記相互作用分析的建議。Schreiber博士在無標簽領域享有盛譽，并主持了許多關于這一主題的會議。

藥物發現和開發應用

以色列 Bio-Rad Haifa 應用團隊經理 Dalia Shezifi 博士專注于與脂質體結合的小分子和肽的無標記分析。她的工作展示了ProteOn脂質體捕獲試劑盒如何用于解決藥物開發中的重要問題，例如在估計新藥的腸道吸收率時小分子藥物與脂質體的結合。

在總結本系列文章時，Bio-Rad 現場應用專家 Gary Ross 介紹了如何使用 ProteOn 系統在一次 45 分鐘的實驗中進行抗體定量和全蛋白質動力學分析。對于參與抗體篩選的研究人員來說，此應用程序是一項重要進展，因為它在單個平臺上的單個實驗中提供了豐富的數據，從而節省了工作臺時間。

“這些演講是激發未來可能進行的新想法和檢測的好方法，”瑞典KTH皇家理工學院的博士生Johan Nilvebrant說。

秋季會，新系列

Bio-Rad 的下一個 SPR 網絡研討會系列將于今年秋季舉行，將于 9 月 25 日拉開帷幕，意大利赫蘭扎諾 DiaSorin 研究中心的研究科學家 Carlotta Chiappa 博士將介紹用于開發艱難梭菌診斷測試的抗體篩選。10 月，Bio-Rad 應用科學家 Jonathan Popplewell 博士將舉辦一場網絡研討會，重點介紹 SPR 數據處理和下游分析的最佳實踐。斯坦福大學醫學院博士后研究員Lisa Scalfone博士將討論ProteOn XPR36系統如何在新的工作流程中用于開發針對流感病毒的抗體。秋季系列的最后一位演講者，捷克共和國布拉格微生物研究所的博士后研究員Ladislav Bumba博士將討論細菌毒素與細菌發病機制中靶細胞分子相互作用的分析。

Bio-Rad Laboratories, Inc. Release: Researchers Use the ProteOn? XPR36 System to Study the Mechanisms Underlying Cancer, Alzheimer's Disease, and Other Conditions

Published: Sep 25, 2012

Hercules, CA — September 25, 2012 — Bio-Rad Laboratories, Inc. announces the extension of the Protein Function Division’s ongoing ProteOn webinar series, which showcases the latest cancer and disease research utilizing the ProteOn XPR36 protein interaction array system, an instrument that uses surface plasmon resonance (SPR) to generate rich, label-free kinetic binding data. Previously presented topics include the use of SPR for the identification and characterization of phosphoinositide signaling lipids that have been linked to cancer and in studies aimed at understanding protein misfolding, aggregation, and tissue deposition associated with neurodegenerative conditions such as Alzheimer’s disease.

“The webinars introduced the latest applications of SPR technology for drug discovery workflows and provided valuable updates on the instrument’s software and hardware,” said Dr Ralf J. Hosse, Antibody Engineering Group Leader at Roche Glycart in Switzerland.

Cancer and Alzheimer’s Disease Applications

In a July 2012 webinar, Dr Lily Sommer of the Paterson Institute for Cancer Research in Manchester, U.K., described the identification and characterization of novel phosphoinositide-binding proteins using the ProteOn XPR36 system. Phosphoinositides are signaling lipids whose misregulation has been linked to cancer. The studies were undertaken using Bio-Rad’s ProteOn liposome capturing kit, which uses DNA hybridization to selectively capture liposomes to detect phosphoinositide-protein interactions.

Marco Gobbi of the Mario Negri Institute in Milan, Italy hosted a webinar session titled “Novel Applications of SPR to Study Amyloidogenic Peptides and Proteins.” He discussed novel SPR screening applications for both mutation analysis and investigating the effects anti-amyloidogenic drug candidates. The results of this work were published in the Journal of Biological Chemistry in June 2012.

An increasing number of diseases are now being associated with misfolding, aggregation, and tissue deposition of specific proteins, such as in Alzheimer’s disease. Soluble oligomers of the amyloid-? (A?) peptide play a key role in the pathogenesis of Alzheimer’s disease, but their elusive nature makes detection challenging. Gobbi and his team demonstrated that SPR measurements can be particularly useful for the kinetic analysis of the elongation of amyloid fibrils and the detection of soluble oligomeric species, which cannot be achieved by other techniques.

Best Practices in SPR

The webinar series kicked off with a session that focused on guidelines developed by Professor Gideon Schreiber of the Weizmann Institute of Science in Israel advising researchers on how to best perform label-free interaction analysis. Dr Schreiber is well known in the label-free field and has hosted and chaired many conferences on this topic.

Drug Discovery and Development Applications

Dr Dalia Shezifi, manager of the Bio-Rad Haifa Applications Team in Israel, focused on label-free analysis of small molecules and peptides binding to liposomes. Her work demonstrated how the ProteOn liposome capturing kits have been used to address important issues in drug development, such as the binding of small molecule drugs to liposomes when estimating the intestinal absorptivity of new drugs.

To conclude the series, Gary Ross, a Bio-Rad field application specialist, described how the ProteOn system was used to perform antibody quantification and full protein kinetic analysis in a single 45-minute experiment. This application is an important advance for researchers involved in antibody screening, as it provides rich data in a single experiment on a single platform, saving bench time.

“The presentations were a good way to inspire new ideas and assays that may be performed in the future,” said Johan Nilvebrant, a PhD student at the KTH Royal Institute of Technology in Sweden.

New Season, New Series

Bio-Rad’s next SPR webinar series will take place this fall, kicking off on Sept. 25 with a presentation by Dr Carlotta Chiappa, a research scientist at the DiaSorin Research Center in Geranzano, Italy, on antibody screening for the development of a diagnostic test for Clostridium difficile. In October, Dr Jonathan Popplewell, a Bio-Rad application scientist, will present a webinar focusing on best practices for SPR data processing and downstream analysis. Dr Lisa Scalfone, a postdoctoral researcher at the Stanford University School of Medicine, will talk about how the ProteOn XPR36 system was used in a novel workflow to develop antibodies against the influenza virus. The last speaker in the fall series, Dr Ladislav Bumba, a postdoctoral researcher at the Institute of Microbiology in Prague, Czech Republic, will discuss the analysis of the interactions of bacterial toxins with target cell molecules in bacterial pathogenesis.